Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, hypertension, and cardiovascular disease.

A retrospective cohort study found that semaglutide and tirzepatide are linked with significantly lower risks of dementia and ...

The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...

New research reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Experts urge ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...

Source: Analyst estimates for the quarter provided by FactSet.

The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...

New medicines have made weight loss easier than ever. But if you also want health and happiness, make these seven psychology ...

Apnimed has scored another phase 3 knockout. The Massachusetts biotech’s daily pill for obstructive sleep apnea reduced the ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

The "try and fail" language is flawed when weight loss is used as the primary measure of success with lifestyle interventions ...

The team found that the tirzepatide-treated mice lost about 20 percent of their body weight, mostly from reduced fat mass. In ...